Morningstar - Atos SE (ATO) We think Atos has some way to go before it rivals industry leaders.

Report

Morningstar

Andrew Lange

EUR 98.48 For Business Accounts Only

We think Atos has some way to go before it rivals industry leaders.

Atos reported a strong finish to fiscal 2016, with better-than-expected revenue growth and operating margins. The companyâ€™s fourth-quarter book/bill ratio of 119% (111% for the year) signifies clientsâ€™ ongoing demand for cybersecurity, automation, cloud migration, and analytics services We believe Atos has been a shrewd organic and inorganic investor in these newer high-demand services, and we have been impressed with its ability to reinvigorate its organic revenue growth rate, which was 1.9% in...

24/04/2017 12 EN

Underlying

Atos SE

Atos is an international information technology services company operating in 52 countries. Co.'s customers are sectors like Public Sector and Utilities, Telecoms and Media, Financial Services, Process Industries and Discrete Manufacturing and Consumer Products and Retail. Co. operates in seven geographical segments: Germany; France; Benelux and The Nordics; U.K. and Ireland; Atos Worldline; Central & Eastern Europe; North America; Iberia; and Other Countries. Co. delivers IT services through the following five segments: Managed Services, Systems Integration, Consulting, Worldline: ePayment Services, and Cloud & Enterprise Software.

See profile

FR0000051732 Euronext Paris France

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Andrew Lange

Other Reports on these Companies

GlobeNewsWire

FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan

FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan Press Release FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan Cash and Profitability Targets ExceededRevenue Target Achieved Book-to-bill in Line with Expectations FY 2025 revenue estimated at €8,001 million - or €8,030 million at September 30 currency, in line with targetInflexion point in top line trajectory reached in Q4 2025: quarter-on-quarter improvement in estimated Group organic revenue performance, to -9...

January 21, 2026 January 21, 2026 1 EN

GlobeNewsWire

Chiffres préliminaires et non audités pour l’exercice 2025, mettant en évidence les progrès significatifs dans l’exécution du plan Genesis

Chiffres préliminaires et non audités pour l’exercice 2025, mettant en évidence les progrès significatifs dans l’exécution du plan Genesis Communiqué de presse Chiffres préliminaires et non audités pour l’exercice 2025, mettant en évidence les progrès significatifs dans l’exécution du plan Genesis Objectifs de cash et de rentabilité dépassésObjectif de chiffre d’affaires atteintRatio book-to-bill en ligne avec les attentes Chiffre d’affaires de l’exercice 2025 estimé à 8 001 millions d’euros – ou 8 030 millions d’euros aux taux de change du 30 septembre, conforme à l’objectif annuelPoint...

January 21, 2026 January 21, 2026 1 EN

SmartInsider

Atos SE: 1 director

A director at Atos SE bought 750 shares at 50.100EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Free Trial

January 8, 2026 January 8, 2026 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

We think Atos has some way to go before it rivals industry leaders.

FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan

Chiffres préliminaires et non audités pour l’exercice 2025, mettant en évidence les progrès significatifs dans l’exécution du plan Genesis

Atos SE: 1 director

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe